CIK 0002036042 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Sionna Therapeutics, Inc.
Sign in to watch- Ticker
- SION
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-819-2020
- Business address
- 21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $21,835,018
- in 1 filing
Net −$21,835,018. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-10 | Atlas Venture Fund XI, L.P. 10% owner | Conversion | +747,727 | 747,727 | ||
| 2025-02-10 | Atlas Venture Fund XI, L.P. 10% owner | Purchase | +60,000 | $18.00 | $1.1M | 807,727 |
| 2025-02-10 | Atlas Venture Fund XI, L.P. 10% owner | Conversion · Series Seed convertible preferred stock | −1,051,051 | 0 | ||
| 2025-02-10 | Atlas Venture Fund XI, L.P. 10% owner | Conversion · Series A convertible preferred stock | −1,806,317 | 0 | ||
| 2025-02-10 | Atlas Venture Fund XI, L.P. 10% owner | Conversion · Series B convertible preferred stock | −1,298,332 | 0 | ||
| 2025-02-10 | Atlas Venture Fund XI, L.P. 10% owner | Conversion · Series C convertible preferred stock | −61,463 | 0 | ||
| 2025-02-10 | Atlas Venture Fund XI, L.P. 10% owner | Conversion · Series C convertible preferred stock | −1,092,504 | 0 | ||
| 2025-02-10 | Booth Bruce Director | Conversion | +2,886,293 | 2,886,293 | ||
| 2025-02-10 | Booth Bruce Director | Conversion | +747,727 | 747,727 | ||
| 2025-02-10 | Booth Bruce Director | Purchase | +60,000 | $18.00 | $1.1M | 807,727 |
| 2025-02-10 | Booth Bruce Director | Conversion · Series Seed convertible preferred stock | −1,051,051 | 0 | ||
| 2025-02-10 | Booth Bruce Director | Conversion · Series A convertible preferred stock | −1,806,317 | 0 | ||
| 2025-02-10 | Booth Bruce Director | Conversion · Series B convertible preferred stock | −1,298,332 | 0 | ||
| 2025-02-10 | Booth Bruce Director | Conversion · Series C convertible preferred stock | −61,463 | 0 | ||
| 2025-02-10 | Booth Bruce Director | Conversion · Series C convertible preferred stock | −1,092,504 | 0 | ||
| 2025-02-10 | ORBIMED ADVISORS LLC Director | Conversion | +3,154,959 | 3,154,959 | ||
| 2025-02-10 | ORBIMED ADVISORS LLC Director | Purchase | +550,000 | $18.00 | $9.9M | 3,704,959 |
| 2025-02-10 | ORBIMED ADVISORS LLC Director | Conversion · Series B convertible preferred stock | −2,560,951 | 0 | ||
| 2025-02-10 | ORBIMED ADVISORS LLC Director | Conversion · Series C convertible preferred stock | −2,048,760 | 0 | ||
| 2025-02-06 | Ruddy Marcella K. Director | Grant or award · Stock Option (Right to Buy) | +39,919 | 39,919 |
Page 14 of 15 · 284 trades